Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.28
+$0.10 · +0.89%
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Regular session
$11.28
+$0.10 · +0.89%
Regular session · ET · Market data may be delayed.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Day range
Current $11.28
52-week range
Current $11.28
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
68
Bullish
Risk
53
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Day range
Current $11.28
52-week range
Current $11.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 68.56M USD | 74.21M USD | 86.18M USD | 1.62B USD | 1.1B USD |
| Cost of goods sold | 11.71M USD | 478.65M USD | 572.83M USD | 620.97M USD | 513.87M USD |
| Gross profit | 56.85M USD | −404.44M USD | −486.65M USD | 994.83M USD | 581.54M USD |
| Research and development | 432.8M USD | 506.5M USD | 579.72M USD | 474.65M USD | 448.01M USD |
| Selling, general, and administrative | 92.07M USD | — | — | — | — |
| Operating expenses | 524.87M USD | 182.73M USD | 197.66M USD | 161.76M USD | 160.79M USD |
| Interest income | 40.24M USD | 71.81M USD | 86.99M USD | 28.09M USD | 439K USD |
| Depreciation and amortization | 11.68M USD | 14.56M USD | 19.45M USD | 6.78M USD | 5.81M USD |
| Operating income | −468.02M USD | −587.17M USD | −684.31M USD | 833.07M USD | 420.75M USD |
| Net income | −437.99M USD | −521.96M USD | −615.06M USD | 515.84M USD | 528.58M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$25.00
121.63% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR69.42M0.06%109.96B USD0.06%$143.45-0.55%
State Street SPDR S&P Biotech ETFXBI60.26M0.52%11.43B USD0.35%$162.32+0.24%
Vanguard Morningstar Total Stock Market ETFVTI41.97M0.00%2.3T USD0.03%$376.41-0.32%
iShares Russell 2000 ETFIWM36.1M0.04%80.51B USD0.19%$292.81-0.63%
Vanguard Morningstar Small-Cap ETFVB30.25M0.02%183.4B USD0.03%$295.79-0.66%
Vanguard Morningstar Small-Cap Growth ETFVBK17.47M0.04%43.8B USD0.05%$345.11-0.80%
iShares Russell 2000 Value ETFIWN13.06M0.09%14.61B USD0.24%$221.81-0.43%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM12.63M0.08%16.56B USD0.03%$55.785-0.55%iShares Core S&P Small-Cap ETFIJRState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Value ETFIWNState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
